A smaller company secures a meeting with a much larger potential partner. The presentation goes well. The questions are engaged, the tone is warm, and both sides agree to stay in touch. Then the follow-up slows. The partner’s team asks for one more piece of information, then another. Months later, the opportunity has quietly faded, and no one can say exactly when it ended.
The pattern is familiar across industries: a regional manufacturer courting a national distributor, a software company pursuing an enterprise channel partner, a growing brand seeking a strategic investor, a young drug developer approaching a global pharmaceutical company. These opportunities are rarely lost in the first meeting. They are lost in the stretch between interest and commitment, when the larger party decides whether the opportunity deserves real internal resources.
That stretch has less to do with the quality of the product than with how the opportunity is framed, sequenced, and sustained. Most companies prepare carefully for the first meeting. Far fewer prepare for what the other side has to do after it.
What Happens on the Other Side of the Table
A large organization does not decide to partner in a single meeting. The person across the table (a business development lead, a corporate development officer, a scout for an operating division) usually cannot say yes alone. Their work after the meeting is to build an internal case: to persuade colleagues with their own priorities, budgets, and competing opportunities that this one deserves diligence time.
That changes what the smaller company should be optimizing for. The goal of the first meeting is not only to impress the person in the room. It is to equip that person to advocate for the opportunity when the smaller company is not in the room. An opportunity that is compelling but hard to explain, hard to fit into the partner’s strategy, or thin on the details a skeptical reviewer will ask about tends to stall, not because anyone rejected it, but because no one had enough to push it forward.
The first meeting is not where the deal is won. It is where the other side decides whether someone will champion it internally.
A Clear Illustration: Biotech Out-Licensing
Few settings show this dynamic more clearly than biotech out-licensing, where smaller developers seek partnerships with global pharmaceutical companies. The demand on the pharmaceutical side is real. Large companies have long depended on outside innovation; by one McKinsey estimate, roughly 45 percent of the drugs in the pipelines of the twenty biopharmaceutical companies with the largest R&D budgets were sourced externally.
Korean biotechs offer a useful example of both the opportunity and the challenge. Their licensing activity has grown substantially, with reported deal value in the first half of 2026 approaching 13 trillion won and on pace for a record year. Yet those figures came with fewer transactions than a year earlier, a sign that much of the value is concentrated in a smaller group of companies, while many others with credible science are still working to turn early interest into diligence. At the same time, global partners are reviewing a growing volume of assets from elsewhere in Asia, particularly China, which accounted for roughly a third of global licensing spending in 2025. A global partner’s attention is increasingly contested.
In that environment, the difference between an opportunity that advances and one that fades is often not the science. It is whether the company has made it easy for the partner to say yes internally.
What Moves an Opportunity Forward
Across industries, a few elements tend to separate the opportunities that advance from those that stall.
The first is a clear answer to “why this, for us, now.” Large partners evaluate opportunities against their own strategy: the therapeutic areas, product lines, markets, or portfolio gaps they are trying to fill. A presentation built around the opportunity’s strengths alone leaves the partner to do the fitting. One that shows the opportunity from the partner{R}s side (where it fits, what gap it addresses, why the timing matters) gives the internal champion a case they can repeat to colleagues.
The second is a package prepared for the skeptic, not only the enthusiast. The person in the first meeting may be persuaded. The colleagues who review the opportunity next will ask harder questions: about the quality of the data, the path to scale or approval, the risks not yet resolved. Anticipating those questions, and having organized and credible answers ready, shortens the path to diligence. Gaps discovered later cost momentum and credibility at the same time.
The third is realistic expectations, framed early. Companies sometimes anchor on headline values from other companies’ deals. A partner that senses a wide gap between the company’s expectations and its own view of value may simply stop engaging rather than negotiate. Understanding how the partner is likely to value the opportunity, and what structure might bridge a difference, keeps the conversation alive long enough to find common ground.
The fourth is disciplined follow-through. Prompt responses, clarity about next steps, and consistent points of contact signal that the company can be a reliable partner for years, not just months. This matters even more across borders, where time zones, language, and different expectations about how decisions are communicated can turn a short delay into a lost quarter. A partner’s silence may reflect an internal process still under way. The smaller company’s silence is usually read as a lack of readiness.
Opportunities rarely fade because someone said no. They fade because no one had enough to say yes.
Preparing for the Second Conversation
For a company pursuing a partnership with a much larger counterparty, the practical question is not only how to succeed in the first meeting, but how to prepare for everything that follows it. A few questions are worth answering beforehand:
Who inside the partner will need to be persuaded, and what will they care about?
Why does this opportunity fit the partner’s strategy now, in the partner’s terms, not ours?
What will a skeptical internal reviewer ask, and are the answers ready?
What is the partner likely to believe the opportunity is worth?
Who on our side owns follow-through, and how quickly can we respond?
Whether the counterparty is a global pharmaceutical company or a national distributor, the principle is the same. A strong opportunity still needs someone on the other side willing to carry it forward. Companies that prepare for that person’s needs, and not only for their own presentation, give the opportunity its best chance of reaching the stage where deals are actually made.
David Y.K. Kim is the Principal Attorney of Crossbridge Law Group, a transactional boutique serving companies, founders and business owners, executives, investors, and private clients on outside general counsel, business transactions, cross-border, strategic advisory, and private client matters. The firm is based in Irvine, California and serves clients across Southern California. He previously practiced at A&O Shearman, served as in-house counsel at Merrill Lynch, and was an investment banker at J.P. Morgan. His work includes advising companies on strategic partnerships with larger counterparties, including cross-border collaborations with global pharmaceutical partners.
